ERBB3 and neoplasm: In this study, we investigate the effects of a novel combinatorial strategy based on the use of a HDACi, such as vorinostat or VPA, plus the anti-ErbB3 MoAb, A3, in a set of primary tumor cultures from malignant pleural effusions (MPEs) of NSCLC patients.